Takayasu ArteritisPhase 2STARSNCT07477795
Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
A Phase 2 study testing Secukinumab in people with Takayasu Arteritis and Large Vessel Vasculitis, run by Assistance Publique - Hôpitaux de Paris.
Trial summary
Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular complication within 10 years from diagnosis. Read more about this study
- Who is it for?
- Ages 15 years and older
- Conditions the study is for
- Takayasu Arteritis, Large Vessel Vasculitis
- What is being tested?
- Secukinumab
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 52 participants
- Where
- No sites listed yet
- Study dates
- 1 Apr 2026to 1 Apr 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 15 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Patients ≥15 years
- Signed informed consent
- Affiliation with the French national social security system.
- Adequate and effective contraceptive measures based on CTFG update of recommendations version 1.1 dated 21-Sep-2020
- For women of childbearing age, a negative serum or urinary pregnancy test.
- Diagnosis of TAK based on the 2022 American College of Rheumatology/EULAR and/or Ishikawa criteria modified by Sharma (Appendix 1) for patients with age ≥ 18 years and based the PRINTO/EULAR/PReS criteria for patients with age between 15 and 17 years
Show all 12Show fewer
- Active TAK defined by a National Institutes of Health [NIH] score >1 in the past 2 months (Appendix 2)
- Severe TAK, defined as either refractory/relapsing disease or by the presence of severe arterial involvement at baseline.
- refractory/relapsing disease is defined as the recurrence or persistence of vasculitis activity confirmed by a specialized physician despite adequate corticosteroid tapering (i.e., inability to taper corticosteroids below 1mg/kg/day within 1 month due to disease activity, or inability to taper corticosteroids below 10mg/day within 6 months, or inability to discontinue corticosteroids after 1 year of treatment, or relapse of disease during/after gradual decrease of corticosteroids therapy) and/or immunosuppressive treatment (e.g., azathioprine, methotrexate, mycophenolate mofetil, leflunomide)
- Severe arterial involvement is defined by the presence of stroke, retinopathy, coronary artery stenosis, pulmonary artery stenosis, mesenteric arteries or celiac trunk stenosis, renal artery stenosis or limb ischemia at baseline.
- Patients must be eligible to receive prednisone (or equivalent) 10-50 mg daily at baseline. Oral corticosteroids must be at a stable dose for at least 2 weeks prior to the first administration of study drug at Day 0.
- Absence of chronic active infections. Patients with a positive TB test may participate in the study if further work up (according to local practice/guidelines) conclusively establishes that the patient has no evidence of active tuberculosis. If the test result is indeterminate, the investigator may repeat the test once or may proceed directly to perform the work-up for TB as per local procedure. If presence of latent tuberculosis is established then treatment according to local country guidelines must be initiated prior to randomization
Who cannot join
- Inability to comply with study guidelines or provide informed consent
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 6 months after stopping of investigational drug. Highly effective contraception methods include:
- Total abstinence (when this is in line with the preferred and usual lifestyle of the participant). Periodic abstinence (e.g., calendar, ovulation, symptotherma), post- ovulation methods) and withdrawal are not acceptable methods of contraception.
- Female bilateral tubal ligation, female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or total hysterectomy at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment.
- Male sterilization (at least 6 months prior to screening). For female participants on the study, the vasectomized male partner should be the sole partner for that participant.
Show all 41Show fewer
- Use of oral (estrogen and progesterone), injected, or implanted hormonal methods of contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS), or other forms of hormonal contraception that have comparable efficacy (failure rate < 1%), for example hormone vaginal ring or transdermal hormone contraception.
- In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
- Contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.
- Women are considered post-menopausal if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age-appropriate history of vasomotor symptoms). Women are considered of not child-bearing potential if • they are post-menopausal or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow-up hormone level assessment is she considered not of child-bearing potential If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the informed consent form (ICF).
- Sexually active males, unless they agree to use barrier protection during intercourse with a woman of child-bearing potential, while taking study treatment. As condom use alone has a reported failure rate exceeding 1% per year, it is recommended that female partners of male study participants use a second method of birth control.
- Globally, for all sexually active males, contraception should be used in accordance with the locally approved prescribing information of concomitant medications administeredPregnancy or breastfeeding;
- History of severe immunosuppression, positive serology for HIV or positive HBsAg
- Infection requiring treatment with intravenous antibiotics within 2 weeks prior to the inclusion \& randomization visit
- Contraindication or hypersensitivity to Secukinumab, TNF inhibitors or tocilizumab, corticosteroids, TB prophylactic treatment or to any of their excipients. For contra-indications related to the standard of care medications refer to the summary of each Product Characteristics (SmPC) refer to EMA links (7.1.2)
- Have received live vaccines within 3 months prior to inclusion
- Indication to initiate infliximab, adalimumab, tocilizumab, secukinumab for another active disease than Takayasu arteritis (retained)
- Use of the following systemic treatments during the specified periods
- Treatment with biologic therapy secukinumab, within 3 months prior to the inclusion \& randomization visit
- Treatment with any systemic alkylating agents within 3 months prior to the inclusion \& randomization visit (e.g., cyclophosphamide, chlorambucil)
- Presence of any of the following on-ongoing and on-treatment disease processes (vasculitis and auto- immunes disease):
- Microscopic polyangiitis
- Granulomatosis with polyangiitis Eosinophilic granulomatosis with polyangiitis
- Polyarteritis nodosa o Cogan's syndrome
- Behcet's disease
- Kawasaki's disease
- Atypical mycobacterial infections
- Deep fungal infections o Lymphoma, lymphomatoid granulomatosis, or other type of malignancy that mimics vasculitis o Cryoglobulinemic vasculitis
- Systemic lupus erythematosus
- Rheumatoid arthritis o Mixed connective tissue disease or any overlap autoimmune syndrome
- Known constitutive immunodeficiency
- History of malignancy in the last 5 years (except adequately treated basal or squamous cell carcinoma of the skin)
- Severe renal impairment (creatinine clearance <30mL/min/1.73m2)
- History of clinically significant liver disease or liver injury as indicated by abnormal liver function tests such as Aspartate Aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP) or serum bilirubin. The investigator should be guided by the following criteria:
- SGOT (AST) and SGPT (ALT) may not exceed 3 × the upper limit of normal (ULN). A single parameter elevated up to and including 3 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
- Alkaline phosphatase may not exceed 4 × ULN. An elevation up to and including 4 × ULN should be re-checked once more as soon as possible, and in all cases, at least prior to randomization, to rule-out laboratory error.
- Total bilirubin may not exceed 4 × ULN. If the total bilirubin concentration is increased above 4 × ULN, total bilirubin should be differentiated into the direct and indirect reacting bilirubin
- Blood count abnormality:
- Platelet count < 50 x 10.3/mm3
- Neutropenia < 1000/mm3
- Haemoglobin < 8 g/dl
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Prospective, Bayesian, Randomized, Controlled, Open-label, Parallel-group, Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular complication within 10 years from diagnosis. TAK inflammation is mediated by T cells and macrophages. Pro-inflammatory Th1 and Th17 cells are dominant infiltrates in the vascular walls, producing IFN-γ and IL-17 to drive the systemic and vascular manifestations of TAK. Currently, TAK patients are principally treated with non-specific steroids, which are associated with potential side effects, especially when used for a long-time course. Steroid treatment preferentially target innate cytokines, such as IL-1β, IL-12, and IL-6 but have little effect on tissue-residing T cells. Novel approach needs to eliminate all T-cell effectors. The use of classical immunosuppressive drugs (IS) (methotrexate, Leflunomide) and biotherapies are prescribed earlier in the management of the disease in order to improve remission, spare corticosteroids and reduce relapses. Data from observational series report remission in 37-76% of cases with anti TNF alpha and 68% with Tocilizumab. However, a placebo-controlled trial failed to show superiority of tocilizumab in TAK.
To date, no immunomodulatory treatment has been approved for the management of TAK and corticosteroids sparing remains a major challenge in this disease. Our team has demonstrated the key role of Th1 and Th17 responses in the pathophysiology of TAK. We found that Th17 and Th1 pathways contribute to the systemic and vascular manifestations of TAK and glucocorticoid treatment suppresses Th1 cytokines but spares Th17 cytokines in patients with TAK. Other teams further confirmed the significant increase in Th17 axis in TAK, and its correlation with disease activity, clinical relapse and arterial fibrosis. Secukinumab is a fully human monoclonal antibody that selectively inhibits IL-17A. Secukinumab received approval for adult treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis, and active ankylosing spondylitis in numerous countries, including the EU and the USA Recently, a phase II clinical trial assessing the efficacy and safety of secukinumab vs placebo in combination with glucocorticoid taper regimen in giant cell arteritis showed that patients with active giant cell arteritis had a higher sustained remission rate in the secukinumab group than in the placebo group at week 28, and is now being studied in a phase 3 study (NCT04930094).Secukinumab was well tolerated with no new safety concerns. In TAK, recent observational data suggested that secukinumab might be an effective alternative to TNFi in severe TAK patients.
Inhibition of IL-17A could represent a potential new therapeutic option for the treatment of severe TAK disease, hence the need for a prospective study to evaluate secukinumab in the management of active severe TAK.
- Conditions
- Takayasu Arteritis, Large Vessel Vasculitis
- Being tested
- Secukinumab, Standard of Care (SOC)
- Keywords
- Takayasu arteritis, Large Vessel Vasculitis
- Medical subject headings
- Takayasu Arteritis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SecukinumabDrug
300 mg subcutaneous Secukinumab at Week 0, 1, 2, 3, 4 and then every 4 weeks until W24 (10 administrations)
Standard of Care (SOC)Other
i.e., TNF inhibitors or tocilizumab, at physician's discretion, according to the French, European and international recommendations
| Study group | Role | What they receive |
|---|---|---|
| secukinumab | Experimental | Not described Receives: Drug: Secukinumab |
| Standard of care | Active comparator | Not described Receives: Other: Standard of Care (SOC) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease remission
Defined by National Institutes of Health (NIH) ≤ 1 at 6 months and with prednisone discontinuation
Measured: At 6 months
Secondary outcomes (16)
Cumulative incidence of relapse
Measured: 12 months after treatment initiation
Cumulative incidence of treatment failure
Measured: 12 months after treatment initiation
Cumulative prednisone dose
Measured: 12, months after treatment initiation
Glucocorticoid-free disease remission
Measured: At 3 months
Glucocorticoid-free disease remission
Measured: At 6 months
Glucocorticoid-free disease remission
Measured: At 12 months
Cumulative incidence of Adverse Events and Serious Adverse Events
Measured: At 12 months
Change in the Physical Component Summary (PCS) of the SF36
The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.
Measured: At 6 months
Change in the Physical Component Summary (PCS) of the SF36
The Short Form (36) Health Survey is a 36-item measure if health status. The score obtained varies between 0 and 100. The higher the score the less disability.
Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 1992;30:473-83.
Measured: At 12 months
Change in vascular lesions
measured by angio CT and/or magnetic resonance imaging angiography and/or Doppler
Measured: At 3 months
Change in vascular lesions
measured by angio CT and/or magnetic resonance imaging angiography and/or Doppler
Measured: At 6 months
Change in vascular lesions
measured by angio CT and/or magnetic resonance imaging angiography and/or Doppler
Measured: At 12 months
Change in vascular hypermetabolism
measured by 18-FDG-PET
Measured: At 6 months
Change in vascular hypermetabolism
measured by 18-FDG-PET
Measured: At 12 months
Cumulative incidence of revascularization procedures (endovascular or surgical) required because of disease
Measured: At 6 months
Cumulative incidence of revascularization procedures (endovascular or surgical) required because of disease
Measured: At 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 Mar 2026
- Study start1 Apr 2026 (estimated)
- Primary completion1 Oct 2029 (estimated)
- Study completion1 Apr 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Takayasu ArteritisStudies of the same condition, open and under way.
- More trials run by Assistance Publique - Hôpitaux de ParisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- multicentre phase 2, two arms, prospective study
- Masking
- None (open label)
- Enrolment
- 52 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07477795
- Sponsor's protocol ID
- APHP240614
- Acronym
- STARS
- Status last verified
- Mar 2026
- First submitted
- 12 Mar 2026
- Last updated
- 27 Mar 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 27 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective, Bayesian, Randomized, Controlled, Open-label, Parallel-group, Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients
- ClinicalTrials.gov ID
- NCT07477795
- Acronym / sponsor ID
- STARS / APHP240614
- Conditions
- Takayasu Arteritis, Large Vessel Vasculitis
- Keywords
- Takayasu arteritis, Large Vessel Vasculitis
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 52 participants (estimated)
- Lead sponsor
- Assistance Publique - Hôpitaux de ParisUniversity, hospital or other
- Study start
- 1 Apr 2026 (estimated)
- Primary completion
- 1 Oct 2029 (estimated)
- Study completion
- 1 Apr 2030 (estimated)
- First posted
- 17 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Takayasu's arteritis (TAK) is a large vessel vasculitis preferentially affecting the aorta and its main branches, leading to wall vessels thickening, fibrosis, stenosis, and occlusion. Patients with TAK have a high morbidity rate, 50% will relapse and experience a vascular complication within 10 years from diagnosis. TAK inflammation is mediated by T cells and macrophages. Pro-inflammatory Th1 and Th17 cells are dominant infiltrates in the vascular walls, producing IFN-γ and IL-17 to drive the systemic and vascular manifestations of TAK. Currently, TAK patients are principally treated with non-specific steroids, which are associated with potential side effects, especially when used for a long-time course. Steroid treatment preferentially target innate cytokines, such as IL-1β, IL-12, and IL-6 but have little effect on tissue-residing T cells. Novel approach needs to eliminate all T-cell effectors. The use of classical immunosuppressive drugs (IS) (methotrexate, Leflunomide) and biotherapies are prescribed earlier in the management of the disease in order to improve remission, spare corticosteroids and reduce relapses. Data from observational series report remission in 37-76% of cases with anti TNF alpha and 68% with Tocilizumab. However, a placebo-controlled trial failed to show superiority of tocilizumab in TAK.
To date, no immunomodulatory treatment has been approved for the management of TAK and corticosteroids sparing remains a major challenge in this disease. Our team has demonstrated the key role of Th1 and Th17 responses in the pathophysiology of TAK. We found that Th17 and Th1 pathways contribute to the systemic and vascular manifestations of TAK and glucocorticoid treatment suppresses Th1 cytokines but spares Th17 cytokines in patients with TAK. Other teams further confirmed the significant increase in Th17 axis in TAK, and its correlation with disease activity, clinical relapse and arterial fibrosis. Secukinumab is a fully human monoclonal antibody that selectively inhibits IL-17A. Secukinumab received approval for adult treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis, and active ankylosing spondylitis in numerous countries, including the EU and the USA Recently, a phase II clinical trial assessing the efficacy and safety of secukinumab vs placebo in combination with glucocorticoid taper regimen in giant cell arteritis showed that patients with active giant cell arteritis had a higher sustained remission rate in the secukinumab group than in the placebo group at week 28, and is now being studied in a phase 3 study (NCT04930094).Secukinumab was well tolerated with no new safety concerns. In TAK, recent observational data suggested that secukinumab might be an effective alternative to TNFi in severe TAK patients.
Inhibition of IL-17A could represent a potential new therapeutic option for the treatment of severe TAK disease, hence the need for a prospective study to evaluate secukinumab in the management of active severe TAK.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- multicentre phase 2, two arms, prospective study
| Arm | Type | Receives |
|---|---|---|
| secukinumab | Experimental | Drug: Secukinumab |
| Standard of care | Active comparator | Other: Standard of Care (SOC) |
Who may qualify
- Ages
- 15 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (12 listed)
- Patients ≥15 years
- Signed informed consent
- Affiliation with the French national social security system.
- Adequate and effective contraceptive measures based on CTFG update of recommendations version 1.1 dated 21-Sep-2020
- For women of childbearing age, a negative serum or urinary pregnancy test.
Key exclusion criteria (41 listed)
- Inability to comply with study guidelines or provide informed consent
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human Chorionic Gonadotropin (hCG) laboratory test.
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception while taking study treatment and for 6 months after stopping of investigational drug. Highly effective contraception methods include:
- In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.
- Contraception should be used in accordance with locally approved prescribing information of concomitant medications administered.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Secukinumab300 mg subcutaneous Secukinumab at Week 0, 1, 2, 3, 4 and then every 4 weeks until W24 (10 administrations) | Drug | secukinumab |
| Standard of Care (SOC)i.e., TNF inhibitors or tocilizumab, at physician's discretion, according to the French, European and international recommendations | Other | Standard of care |
Primary outcome
Disease remission
Time frame: At 6 months
Defined by National Institutes of Health (NIH) ≤ 1 at 6 months and with prednisone discontinuation
16 secondary outcomes
Cumulative incidence of relapse
Time frame: 12 months after treatment initiation
Cumulative incidence of treatment failure
Time frame: 12 months after treatment initiation
Cumulative prednisone dose
Time frame: 12, months after treatment initiation
Glucocorticoid-free disease remission
Time frame: At 3 months
Glucocorticoid-free disease remission
Time frame: At 6 months
Glucocorticoid-free disease remission
Time frame: At 12 months
Cumulative incidence of Adverse Events and Serious Adverse Events
Time frame: At 12 months
Change in the Physical Component Summary (PCS) of the SF36
Time frame: At 6 months
Change in the Physical Component Summary (PCS) of the SF36
Time frame: At 12 months
Change in vascular lesions
Time frame: At 3 months
Change in vascular lesions
Time frame: At 6 months
Change in vascular lesions
Time frame: At 12 months
Change in vascular hypermetabolism
Time frame: At 6 months
Change in vascular hypermetabolism
Time frame: At 12 months
Cumulative incidence of revascularization procedures (endovascular or surgical) required because of disease
Time frame: At 6 months
Cumulative incidence of revascularization procedures (endovascular or surgical) required because of disease
Time frame: At 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Mar 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Takayasu Arteritis
RecruitingObservational study
Studies of the Natural History, Pathogenesis, and Outcome of Idiopathic Systemic Vasculitis
Takayasu's Arteritis, Giant Cell Arteritis
Not yet recruiting
Long-Axial Field of View (LAFOV) [18F]FDG PET/CT Imaging in Large Vessel Vasculitis (LVV): Protocol Optimisation Study.
Large Vessel Vasculitis, Takayasu Arteritis
RecruitingObservational study
Treatment of Patients With Takayasu Arteritis Complicated With Pulmonary Artery Involvement
Takayasu Arteritis With Pulmonary Artery Involvement, Percutaneous Transluminal Pulmonary Angioplasty
Not yet recruitingObservational study
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
RecruitingPhase 4
Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Rheumatoid Arthritis (RA), Juvenile Idiopathic Arthritis (JIA)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Secukinumab in people with Takayasu Arteritis and Large Vessel Vasculitis, run by Assistance Publique - Hôpitaux de Paris.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 12 inclusion and 41 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact David Saadoun, MD PhD (+33 1 42 17 80 42 ext. +33, david.saadoun@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease remission (time frame: At 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Mar 2026.